Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Rapamycin for Vitiligo
NCT05342519Phase 2Active, not recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sirolimus in Vitiligo (3 arms), sponsored by Medical University of South Carolina. Primary endpoints: Number of lesions with no response at 6 months, Number of lesions with partial response at 6 months and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05342519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342519.